196 related articles for article (PubMed ID: 37345658)
1. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
Hu Y; Paris S; Sahoo N; Bertolet G; Wang Q; Wang Q; Barsoumian HB; Da Silva J; Huang A; Doss DJ; Pollock DP; Hsu E; Selene N; Leyton CSK; Voss TA; Masrorpour F; Ganjoo S; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37345658
[TBL] [Abstract][Full Text] [Related]
2. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y; Paris S; Bertolet G; Barsoumian HB; Wang Q; Da Silva J; Patel NB; Nguyen N; Doss DJ; Huang A; Hsu E; Leyton CSK; Voss TA; Masrorpour F; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
Front Immunol; 2022; 13():1022011. PubMed ID: 36405757
[TBL] [Abstract][Full Text] [Related]
3. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y; Paris S; Bertolet G; Barsoumian HB; He K; Sezen D; Chen D; Wasley M; Silva JD; Mitchell JA; Voss TA; Masrorpour F; Leyton CK; Yang L; Leuschner C; Puebla-Osorio N; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
J Nanobiotechnology; 2022 Sep; 20(1):417. PubMed ID: 36123677
[TBL] [Abstract][Full Text] [Related]
4. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
Hu Y; Paris S; Barsoumian H; Abana CO; He K; Sezen D; Wasley M; Masrorpour F; Chen D; Yang L; Dunn JD; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
J Nanobiotechnology; 2021 Dec; 19(1):416. PubMed ID: 34895262
[TBL] [Abstract][Full Text] [Related]
5. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
Hu Y; Paris S; Barsoumian H; Abana CO; He K; Wasley M; Younes AI; Masrorpour F; Chen D; Yang L; Dunn JD; Zhang J; Gandhi S; Nguyen QN; Cortez MA; Welsh J
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):647-657. PubMed ID: 34242713
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
[TBL] [Abstract][Full Text] [Related]
7. Integration of radiation and immunotherapy in breast cancer - Treatment implications.
Ye JC; Formenti SC
Breast; 2018 Apr; 38():66-74. PubMed ID: 29253718
[TBL] [Abstract][Full Text] [Related]
8. Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.
Lee HJ; Zeng J; Rengan R
Transl Lung Cancer Res; 2018 Apr; 7(2):180-188. PubMed ID: 29876317
[TBL] [Abstract][Full Text] [Related]
9. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
Barsoumian HB; Ramapriyan R; Younes AI; Caetano MS; Menon H; Comeaux NI; Cushman TR; Schoenhals JE; Cadena AP; Reilly TP; Chen D; Masrorpour F; Li A; Hong DS; Diab A; Nguyen QN; Glitza I; Ferrarotto R; Chun SG; Cortez MA; Welsh J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106386
[TBL] [Abstract][Full Text] [Related]
10. Proton Therapy in Non-small Cell Lung Cancer.
Mesko S; Gomez D
Curr Treat Options Oncol; 2018 Nov; 19(12):76. PubMed ID: 30483900
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
[TBL] [Abstract][Full Text] [Related]
12. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
13. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
14. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
15. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
16. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.
Hartmann L; Osen W; Eichmüller OL; Kordaß T; Furkel J; Dickes E; Reid C; Debus J; Brons S; Abdollahi A; Moustafa M; Rieken S; Eichmüller SB
Cancer Lett; 2022 Dec; 550():215928. PubMed ID: 36183858
[TBL] [Abstract][Full Text] [Related]
17. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
[TBL] [Abstract][Full Text] [Related]
19. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
